Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced...
Imago BioSciences press release (NASDAQ:IMGO): Q1 GAAP EPS of -$0.49 misses by $0.06. As of March 31, 2022, Imago had cash and cash equivalents and short-term investments of $205.8 million, compared to $82.7 million as of March 31, 2021 and $217.4 million as of December 31, 2021. For furthe...
- Completed Type C meeting with FDA to align on study design, study population, control group and primary endpoint for planned Phase 3 essential thrombocythemia (ET) study - Enrollment completed in Phase 2 trial of bomedemstat for treatment of ET - Additional data from P...
SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone m...
SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marro...
Interim Data Update at European Hematology Association (EHA) meeting in June and Results from Completed Phase 2 Study Expected in Second Half of 2022 End-of-Phase 2 Meeting with U.S. Food and Drug Administration (FDA) Expected in Second Half of 2022 SOUTH SAN FRANCISCO, ...
Imago BioSciences press release (NASDAQ:IMGO): FY Cash cash and equivalents for short term $217.4M Net loss of $42.3M. For further details see: Imago BioSciences reports FY results
SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc . (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow d...
Michael Arenberg, a distinguished biopharmaceutical executive, has joined biopharmaceutical company Imago BioSciences (NASDAQ:IMGO) as Chief Operating and Business Officer. Mr. Arenberg holds over 25 years of experience within the biopharmaceutical, healthcare and medical device industries. H...
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced that Hugh Y. ...
News, Short Squeeze, Breakout and More Instantly...
Imago BioSciences Inc. Company Name:
IMGO Stock Symbol:
NASDAQ Market:
Imago BioSciences Inc. Website:
NEW YORK, NY / ACCESSWIRE / December 27, 2022 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Imago BioSciences, Inc. (NASDAQ: IMG...
NEW YORK, NY / ACCESSWIRE / December 23, 2022 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Lakeland Bancorp, Inc. (NASDAQ:LBAI)...